174 related articles for article (PubMed ID: 19891779)
1. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
Inbar-Rozensal D; Castiel A; Visochek L; Castel D; Dantzer F; Izraeli S; Cohen-Armon M
Breast Cancer Res; 2009; 11(6):R78. PubMed ID: 19891779
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Frizzell KM; Kraus WL
Breast Cancer Res; 2009; 11(6):111. PubMed ID: 20017885
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
5. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.
Wesierska-Gadek J; Schloffer D; Gueorguieva M; Uhl M; Skladanowski A
Cancer Res; 2004 Jul; 64(13):4487-97. PubMed ID: 15231658
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.
Efimova EV; Mauceri HJ; Golden DW; Labay E; Bindokas VP; Darga TE; Chakraborty C; Barreto-Andrade JC; Crawley C; Sutton HG; Kron SJ; Weichselbaum RR
Cancer Res; 2010 Aug; 70(15):6277-82. PubMed ID: 20610628
[TBL] [Abstract][Full Text] [Related]
10. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
11. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
[TBL] [Abstract][Full Text] [Related]
12. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
[TBL] [Abstract][Full Text] [Related]
14. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines.
Lin PH; Lin CH; Huang CC; Chuang MC; Lin P
Toxicol Lett; 2007 Aug; 172(3):146-58. PubMed ID: 17669606
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Comen EA; Robson M
Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
Simbulan-Rosenthal CM; Rosenthal DS; Luo R; Li JH; Zhang J; Smulson ME
Nucleic Acids Res; 2001 Feb; 29(3):841-9. PubMed ID: 11160908
[TBL] [Abstract][Full Text] [Related]
18. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
